Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells

Jun Kuwahara, Takaaki Yamada, Nobuaki Egashira, Mitsuyo Ueda, Nina Zukeyama, Soichiro Ushio, Satohiro Masuda

研究成果: ジャーナルへの寄稿記事

22 引用 (Scopus)

抄録

The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.

元の言語英語
ページ(範囲)1410-1414
ページ数5
ジャーナルBiological and Pharmaceutical Bulletin
38
発行部数9
DOI
出版物ステータス出版済み - 9 1 2015

Fingerprint

Serotonin Uptake Inhibitors
Sertraline
Hep G2 Cells
Hepatocellular Carcinoma
Neoplasms
Cell Survival
Fluvoxamine
Caspase 7
Paroxetine
Citalopram
Caspases
Caspase 3
Serotonin and Noradrenaline Reuptake Inhibitors
Pharmaceutical Preparations
Duloxetine Hydrochloride
milnacipran

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

これを引用

Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells. / Kuwahara, Jun; Yamada, Takaaki; Egashira, Nobuaki; Ueda, Mitsuyo; Zukeyama, Nina; Ushio, Soichiro; Masuda, Satohiro.

:: Biological and Pharmaceutical Bulletin, 巻 38, 番号 9, 01.09.2015, p. 1410-1414.

研究成果: ジャーナルへの寄稿記事

@article{6ba34006086d4100b6f87cc9d691e2fc,
title = "Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells",
abstract = "The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.",
author = "Jun Kuwahara and Takaaki Yamada and Nobuaki Egashira and Mitsuyo Ueda and Nina Zukeyama and Soichiro Ushio and Satohiro Masuda",
year = "2015",
month = "9",
day = "1",
doi = "10.1248/bpb.b15-00128",
language = "English",
volume = "38",
pages = "1410--1414",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

TY - JOUR

T1 - Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells

AU - Kuwahara, Jun

AU - Yamada, Takaaki

AU - Egashira, Nobuaki

AU - Ueda, Mitsuyo

AU - Zukeyama, Nina

AU - Ushio, Soichiro

AU - Masuda, Satohiro

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.

AB - The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.

UR - http://www.scopus.com/inward/record.url?scp=84941142845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941142845&partnerID=8YFLogxK

U2 - 10.1248/bpb.b15-00128

DO - 10.1248/bpb.b15-00128

M3 - Article

C2 - 26328498

AN - SCOPUS:84941142845

VL - 38

SP - 1410

EP - 1414

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -